Cade, D., Pal, S. K., Scott, A. M., Faivre, T. (2026). Phase 3 study to assess the safety and efficacy of
                    <sup>177</sup>
                    Lu-girentuximab in advanced, relapsed, or recurrent ccRCC (LUTEON).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps4631